Overview
Atorvia is a pre-clinical stage Biotech company on a journey to develop ground-breaking technologies in areas of high unmet need & where commercial whitespace exists. With a primary focus on acute & emergency care, we are on a mission to transform outcomes by translating great science into technologies regulators will approve, providers will adopt and for which payors will pay. Our lead program prevents and treats ischemia induced organ damage by antagonizing formation of the necleophosmin-Bax complex responsible for mitochondrial injury and cell death. With a first indication in the kidney, we are developing a peptide-based therapeutic to develop and treat Acute Kidney Injury which remains a large-scale condition with no effective treatment available.